<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908567</url>
  </required_header>
  <id_info>
    <org_study_id>AM-125-CL-18-01</org_study_id>
    <secondary_id>2018-002474-52</secondary_id>
    <nct_id>NCT03908567</nct_id>
  </id_info>
  <brief_title>AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery</brief_title>
  <acronym>TRAVERS</acronym>
  <official_title>Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auris Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of vertigo after removal of a tumor of the balance and hearing nerve after
      neurosurgery, which damages or cuts the vestibular nerve (balance).

      This trial explores the efficacy and safety of AM-125 in the treatment of acute vertigo. In
      this proof of concept trial patients experiencing vertigo after neurosurgery (vestibular
      schwannoma labyrinthectomy and vestibular neurectomy) will receive AM-125 or placebo. It
      evaluates the potential of AM-125 versus placebo in reducing the symptoms of vestibular
      dysfunction and accelerating vestibular compensation following neurosurgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For intranasal subjects, allocation is blinded. The oral arm is an open-label arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of time standing on foam (eyes closed)</measure>
    <time_frame>Day 3 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in tandem Romberg test (eyes closed)</measure>
    <time_frame>Day 3 to Day 14</time_frame>
    <description>Participants will be asked to stand straight in tandem stand (heel of one foot touching the toes of the other foot) and duration in this position will be measured.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Vestibular Vertigo</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal spray solution without active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg AM-125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg AM-125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg AM-125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral 16 mg betahistine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Drug</intervention_name>
    <description>Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day</description>
    <arm_group_label>1 mg AM-125</arm_group_label>
    <arm_group_label>10 mg AM-125</arm_group_label>
    <arm_group_label>20 mg AM-125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tablet</intervention_name>
    <description>Oral dosing with tablets 3 times a day</description>
    <arm_group_label>Oral 16 mg betahistine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intranasal Placebo</intervention_name>
    <description>Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Scheduled for neurosurgery (vestibular schwannoma resection, labyrinthectomy or
             vestibular neurectomy).

          2. Small to moderately large vestibular schwannoma (Koos grade I-III; Samii grade T1-T3b;
             â‰¤ 30 mm in diameter in cerebellopontine angle) that does not displace the brainstem,
             documented by magnetic resonance imaging not older than six months or Indication for
             labyrinthectomy or vestibular neurectomy.

          3. Confirmed vestibular function on both sides.

        Main Exclusion Criteria:

          1. Prior radiotherapy (gammaknife, intensity modulated radiation therapy) irradiating the
             brain-stem with more than 4 Gy.

          2. Any ongoing other peripheral vestibular disorder (e.g. Meniere's disease, benign
             paroxysmal vertigo, vestibular neuritis) or central vestibular disorder (e.g.
             vestibular migraine, central vertigo).

          3. Vestibular rehabilitation therapy or presurgical gentamicin therapy (i.e.
             &quot;pre-habilitation therapy&quot;) within the past three months prior neurosurgery.

          4. Any clinically relevant nasal obstruction or pathology precluding effective and/or
             safe intranasal delivery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Auris Medical</last_name>
    <phone>0041 61 201 1350</phone>
    <email>hear@aurismedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHP Clairval</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://aurismedical.com/product-candidates/am-125</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vertigo</keyword>
  <keyword>Balance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

